간행물

대한장연구학회> Intestinal research (Intest Res)

Intestinal research (Intest Res) update

  • : 대한장연구학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • : SCOPUS
  • : 연속간행물
  • : 계간
  • : 1598-9100
  • : 2288-1956
  • :

수록정보
수록범위 : 1권1호(2003)~20권2호(2022) |수록논문 수 : 893
Intestinal research (Intest Res)
20권2호(2022년 04월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

1Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?

저자 : Yong Eun Park

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 157-158 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

2Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?

저자 : Sang Hyoung Park

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 159-164 (6 pages)

다운로드

(기관인증 필요)

초록보기

Inflammatory bowel disease (IBD) has become a global disease. As IBD is a chronic disease that can result in remarkable morbidity and disability, estimation and understanding the disease burden of IBD is imperative to prepare adequate health care systems. However, variations in IBD incidence or prevalence may reflect differences in the distribution, and there are regional disparities in Asia with a large population of approximately 4.6 billion in 2020, which is equivalent to 60% of the total world population. Although comprehensive understanding of the epidemiology of IBD in Asian countries is difficult, this review includes updated data regarding the incidence and prevalence of IBD and the estimated disease burden in Asia. (Intest Res 2022;20:159-164)

KCI등재 SCOPUS

3Artificial intelligence for endoscopy in inflammatory bowel disease

저자 : Kento Takenaka , Ami Kawamoto , Ryuichi Okamoto , Mamoru Watanabe , Kazuo Ohtsuka

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 165-170 (6 pages)

다운로드

(기관인증 필요)

초록보기

Inflammatory bowel disease (IBD), with its 2 subtypes, Crohn's disease and ulcerative colitis, is a complex chronic condition. A precise definition of disease activity and appropriate drug management greatly improve the clinical course while minimizing the risk or cost. Artificial intelligence (AI) has been used in several medical diseases or situations. Herein, we provide an overview of AI for endoscopy in IBD. We discuss how AI can improve clinical practice and how some components have already begun to shape our knowledge. There may be a time when we can use AI in clinical practice. As AI systems contribute to the exact diagnosis and treatment of human disease, we should continue to learn best practices in health care in the field of IBD. (Intest Res 2022;20:165-170)

KCI등재 SCOPUS

4SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

저자 : Yoo Jin Lee , Seong-eun Kim , Yong Eun Park , Ji Young Chang , Hyun Joo Song , Duk Hwan Kim , Young Joo Yang , Byung Chang Kim , Jae Gon Lee , Hee Chan Yang , Miyoung Choi , Seung-jae Myung

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 171-183 (13 pages)

다운로드

(기관인증 필요)

초록보기

Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy. (Intest Res 2022;20:171-183)

KCI등재 SCOPUS

5Addition of computed tomography chest increases the diagnosis rate in patients with suspected intestinal tuberculosis

저자 : Saurabh Kedia , Raju Sharma , Sudheer Kumar Vuyyuru , Deepak Madhu , Pabitra Sahu , Bhaskar Kante , Prasenjit Das , Ankur Goyal , Karan Madan , Govind Makharia , Vineet Ahuja

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 184-191 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Intestinal tuberculosis (ITB) is difficult to diagnose due to poor sensitivity of definitive diagnostic tests. ITB may be associated with concomitant pulmonary tuberculosis (PTB) which may remain undetected on chest X-ray. We assessed the role of contrast enhanced computed tomography (CECT) chest in detecting the prevalence of active PTB, and increasing the diagnostic yield in patients with suspected ITB. Methods: Consecutive treatment naïve patients with suspected ITB (n=200) who underwent CECT chest (n=88) and had follow-up duration>1 year were recruited in this retrospective study (February 2016 to October 2018). ITB was diagnosed in the presence of caseating granuloma, positive acid fast stain or culture for Mycobacterium tuberculosis on biopsy, presence of necrotic lymph nodes (LNs) on CT enterography or positive response to anti-tubercular therapy. Evidence of active tuberculosis on CECT-chest was defined as presence of centrilobular nodules with or without consolidation/miliary nodules/thick-walled cavity/enlarged necrotic mediastinal LNs. Results: Sixty-five of eighty-eight patients (mean age, 33.8±12.8 years; 47.7% of females) were finally diagnosed as ITB (4-caseating granuloma on biopsy, 12-necrotic LNs on CT enterography, 1-both, and 48-response to anti-tubercular therapy) and 23 were diagnosed as Crohn's disease. Findings of active TB on CECT chest with or without necrotic abdominal LNs were demonstrated in 5 and 20 patients, respectively. No patient with Crohn's disease had necrotic abdominal LNs or active PTB. Addition of CECT chest in the diagnostic algorithm improved the sensitivity of ITB diagnosis from 26.2% to 56.9%. Conclusions: Addition of CECT chest significantly improves the sensitivity for definite diagnosis in a patient with suspected ITB. (Intest Res 2022;20:184-191)

KCI등재 SCOPUS

6Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

저자 : Eun Soo Kim , Chung Hyun Tae , Sung-ae Jung , Dong Il Park , Jong Pil Im , Chang Soo Eun , Hyuk Yoon , Byung Ik Jang , Haruhiko Ogata , Kayoko Fukuhara , Fumihito Hirai , Kazuo Ohtsuka , Jing Liu , Qian

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 192-211 (20 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile the prevalence and pattern of CAM use among East Asian IBD patients and to identify factors associated with CAM use. We also compared physicians' perspectives on CAM. Methods: Patients with IBD from China, Japan, and South Korea were invited to complete questionnaires on CAM use. Patient demographic and clinical data were collected. Logistic regression analysis was applied for predictors of CAM use. Physicians from each country were asked about their opinion on CAM services or products. Results: Overall, 905 patients with IBD participated in this study (China 232, Japan 255, and South Korea 418). Approximately 8.6% of patients with IBD used CAM services for their disease, while 29.7% of patients sought at least 1 kind of CAM product. Current active disease and Chinese or South Korean nationality over Japanese were independent predictors of CAM use. Chinese doctors were more likely to consider CAM helpful for patients with IBD than were Japanese and South Korean doctors. Conclusions: In 8.6% and 29.7% of East Asian patients with IBD used CAM services and products, respectively, which does not differ from the prevalence in their Western counterparts. There is a significant gap regarding CAM usage among different Asian countries, not only from the patients' perspective but also from the physicians' point of view. (Intest Res 2022;20:192-202)

KCI등재 SCOPUS

7Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study

저자 : Sun-ho Lee , Sung Wook Hwang , Sang Hyoung Park , Dong-hoon Yang , Jeong-sik Byeon , Seung-jae Myung , Suk-kyun Yang , Byong Duk Ye

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 203-213 (11 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn's disease (CD) patients. Methods: We prospectively enrolled 49 CD patients in clinical remission (Crohn's Disease Activity Index [CDAI] <150 for the past 6 months). Patients were followed for a median period of 4.4 years (interquartile range [IQR], 4.3-4.5). The following outcomes were evaluated: clinical relapse, CD-related hospitalization, step-up of medical treatment, and CD-related intestinal resection. Cox proportional-hazard regression model was constructed to assess the association of baseline markers with time-to-event outcomes. Results: The median levels of baseline FS, FC, and SS were 0.042 mg/kg (IQR, 0.005-0.179), 486.8 mg/kg (IQR, 203.5-886.8) and 1,398.2 ng/mL (IQR, 791.8-2,759.9), respectively. FS correlated with FC (r=0.689), erythrocyte sedimentation rate (r=0.524), C-reactive protein (r=0.499), and albumin (r=-0.446), but not with CDAI (r=0.045). Interestingly, increased FS (top quartile) was associated with a 4.9-fold increased rate of future CD-related hospitalization (P=0.009) and a 2.8-fold increased rate of step-up of medical treatment (P=0.032), whereas increased FC and SS were not. These findings remained significant after adjusting for age, sex, disease duration, current smoking, C-reactive protein, serum albumin, CDAI, and FC, individually. Conclusions: In this pilot study, increased FS and not FC or SS, was significantly associated with increased rates of future CD-related hospitalization and step-up of medical treatment among CD patients in clinical remission. (Intest Res 2022;20:203-212)

KCI등재 SCOPUS

8Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

저자 : Chenwen Cai , Juntao Lu , Lijie Lai , Dongjuan Song , Jun Shen , Jinlu Tong , Qing Zheng , Kaichun Wu , Jiaming Qian , Zhihua Ran

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 213-227 (15 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: The incidence and prevalence of inflammatory bowel disease (IBD) is rising in Asia recently. The study aimed to obtain a comprehensive understanding of the current status of drug therapy and monitoring for IBD in Asia. Methods: A questionnaire investigation on drug therapy and monitoring for IBD was conducted right before the 6th Annual Meeting of Asian Organization for Crohn's & Colitis. Questionnaires were provided to Asian physicians to fill out via emails between March and May 2018. Results: In total, responses of 166 physicians from 129 medical centers were included for analysis. Among the surveyed regions, the most average number of IBD specialist gastroenterologists and nurses was 4.8 per center in Taiwan and 2.5 per center in Mainland China, respectively. 5-Aminosalicylic acid/sulfasalazine (99.4%) was the most preferred first-line choice for mild-moderate ulcerative colitis (UC), meanwhile corticosteroid (83.7%) was widely applied for severe UC. The first-line medication for Crohn's disease (CD) markedly varied as corticosteroid (68.1%) was the most favored in Mainland China, Japan, and South Korea, followed by infliximab (52.4%) and azathioprine (47.0%). Step-up strategy was preferred in mild-moderate UC (96.4%), while 51.8% of the physicians selected top-down treatment for CD. Only 25.9% and 17.5% of the physicians could test blood concentration of infliximab and antibody to infliximab in their hospitals, respectively. Conclusions: The current status of drug therapy and monitoring for IBD in Asia possesses commonalities as well as differences. Asian recommendations, IBD specialist teams and practice of therapeutic drug monitoring are required to improve IBD management in Asia. (Intest Res 2022;20:213-223)

KCI등재 SCOPUS

9Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease

저자 : Meng-tzu Weng , I-lun Shih , Chien-chih Tung , Yew-loong Leong , Ming-jium Shieh , Cheng-yi Wang , Jau-min Wong , Yen-hsuan Ni , Shu-chen Wei

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 224-231 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD). We aimed to evaluate the prevalence, clinical manifestation, and outcomes of PSC in Taiwanese patients with IBD. Methods: This retrospective study enrolled patients with IBD admitted from January 1, 1996, to December 31, 2018, to National Taiwan University Hospital. A case-matched analysis was performed comparing patients with IBD with and without PSC according to age, sex, and time of admission, with ratios of 1:4 and 1:2 in the adult and pediatric groups, respectively. Results: In total, 763 patients with IBD were enrolled, 12 of whom were also diagnosed with PSC (1.57%). All these patients had ulcerative colitis (UC). A greater incidence of IBD with PSC was observed in younger patients than in older patients. Male sex was a risk factor for PSC in pediatric patients with IBD (P=0.015); 75% of these patients were diagnosed with PSC along with or after the diagnosis of UC. There was no significant difference in colitis extent and severity between the groups; however, a higher proportion of rectal sparing was observed in patients with PSC (P=0.001). There was no significant difference in cancer development between the groups (P=0.679). Conclusions: A 1.57% prevalence of PSC was observed in Taiwanese patients with IBD. The majority of patients with IBD and PSC were men and were diagnosed at a younger age. Hence, routine evaluation of biliary enzymes and liver imaging is recommended in young male patients with IBD. (Intest Res 2022;20:224-230)

KCI등재 SCOPUS

10Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn's disease: a pilot study

저자 : Bhaskar Kante , Pabitra Sahu , Saurabh Kedia , Sudheer K. Vuyyuru , Kapil Soni , Maneesh Singhal , Raju Sharma , Govind Makharia , Vineet Ahuja

발행기관 : 대한장연구학회 간행물 : Intestinal research (Intest Res) 20권 2호 발행 연도 : 2022 페이지 : pp. 231-242 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Existing therapeutic options for complicated Crohn's disease (CD) like biologics and surgery are limited by inadequate long-term efficacy, cost, and adverse effects. Tissue hypoxia is important in CD pathogenesis and may be ameliorated with hyperbaric oxygen therapy (HBOT). We assessed the efficacy and tolerability of HBOT in small bowel stricturing CD. Methods: This pilot study included patients of small bowel stricturing CD (from April 2019 to January 2020) who underwent HBOT. These patients were refractory to conventional medical treatment or had multiple strictures not amenable to resection. Each session of HBOT was given for 60 minutes with a pressure of 1.5-2.5 atm. Clinical, biochemical responses and Short Inflammatory Bowel Disease (SIBD) questionnaire were evaluated at 2 and 6 months, and radiological response was evaluated at 6 months. Results: Fourteen patients (mean age, 42.9±15.7 years; male, 50%) were subjected to 168 HBOT sessions. Thirteen patients (92.7%) had strictures and 1 patient had enterocutaneous fistula in addition. Median number of HBOT sessions was 11 (range, 3-20) which were administered over a median of 4 weeks. Most patients tolerated it well except 1 who had hemotympanum. At 2 and 6 months of follow-up, 64.2% of patients had a clinical response, 50% and 64.2% of patients had clinical remission respectively. Steroid-free clinical remission was seen in 8 (57%) of patients with radiological improvement in 50%. There was a significant improvement in SIBD scores at 2-month follow-up (59.4 vs. 44.5, P=0.03). Conclusions: HBOT can be a safe and effective therapeutic option in patients with stricturing small bowel CD refractory to conventional medical treatment. (Intest Res 2022;20:231-239)

12
권호별 보기

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기